Martin R. Farlow, M.D.

Professor and Vice Chairman of Research, Department of Neurology
Associate Director, Indiana Alzheimer Disease Center

Education/ Training:
M.D. Indiana University School of Medicine, Indianapolis (1979)

Pharmacogenetics, Molecular Markers, and Animal Models of Alzheimer's Disease, Drug Development.

I have broad interests in clinical research with the major focus being Alzheimer's disease. Our group has been following a large cohort of patients with Alzheimers disease, other dementias and age-matched controls for the last 12 years to support a variety of studies seeking: i. to identify new forms of familial dementias and to identify their causative genes; ii. For supporting clinicopathological correlations and neuropathological research; iii. to support phase I, II, III clinical trials of therapeutic agents to improve symptoms and or to slow progression of Alzheimer's disease.

A methodology has been established to facilitate assessing the effects of drugs on the central nervous system by catheterizing the subarachnoid space in volunteers and simultaneously measuring peripheral and cerebrospinal fluid levels of drugs and the proteins they may affect.

We are interested in the role of inflammatory mechanisms and how they facilitate disease progression in Alzheimer's disease. Ongoing studies range from investigating interleukins and other relevant proteins for disease associations, to studies of these agents that selectively inhibit iNOS and caspases in animal models.

Recent Publications:

Du Y, Dodel RC, Hampel H, Buerger K, Lin SZ, Eastwood B, Bales KR, Gao F, Lohmuller F, Moeller H-J, Oertel WH, Farlow M and Paul SM. Reduced levels of amyloid ?-peptide antibody in Alzheimer disease. Neurology 57:801-805; 2001.

Grundman M, Farlow MR, Peavy G, Kim HT, Capparelli E, Schultz AN, Salmon DP, Ferris SH, Mohs R, Thomas RG, Schafer K, Campbell K, Hake AM, Schoos B, Thal LJ and the Alzheimer's Disease Cooperative Study. A Phase I study of AIT-082 in healthy elderly volunteers. Journal of Molecular Neuroscience 18:283-293; 2002.

Gao F, Bales KR, Dodel RC, Liu J, Chen X, Hample H, Farlow MR, Paul ST and Du Y. NF-?B mediates IL-1ß-induced synthesis/release of a2-macroglobulin in a human glial cell line. Molecular Brain Research 105: 108-114; 2002.

Zubenko GS, Zubenko WN, McPherson S, Spoor E, Marin DB, Farlow MR, Smith GE, Geda YE, Cummings JL, Petersen RC and Sunderland T. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. American Journal of Psychiatry 160:5: 857-866; 2003.

Farlow M, Potkin S, Koumaras B, Veach J and Mirski D. Analysis of outcome in retrieved drop-out patients in a rivastigmine versus placebo 26-week, Alzheimer's disease trial. Archives of Neurology 60:843-848; 2003

Aisen PS, Schafer K, Grundman M, Pfeiffer E, Sano M, Davis K, Farlow M, Jin S, Thomas R and Thal LJ for the Alzheimer's Disease Cooperative Study. Results of a multicenter randomized trial of Rofecoxib and Naproxen in Alzheimer ‘s disease.Journal of the American Medical Association 289(21):2819-2826; 2003.

Stark Neurosciences Research Institute | Neuroscience Research Building | 320 West 15th Street | Indianapolis, IN 46202 | Phone: (317) 278-5848 | FAX: (317) 231-0203